GUMDROP : JHMI J1103 Randomized, Double-Blind, Phase 3 Trial to Compare the Efficacy of Ipilimumab vs Placebo in Asymptomatic or Minimally Symptomatic Patients with Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer

Created by Channing Paller, last modified on Apr 14, 2012

Description:

This trial seeks to determine the effective of ipilumab on overall survival and progression free survival of castrate-resistant prostate cancer patients who have progressed on hormonal treatment (showing rising PSA, progressive disease per bone scan or measurable disease on CT); asymptomatic or minimally symptomatic disease; NO visceral metastases; NO prior immunotherapy,chemotherapy, or radioisotope therapy.

Link:

http://clinicaltrials.gov/ct2/show/NCT01057810

Site:

Johns Hopkins Hospital

Principal Investigator:

Charles Drake, M.D.